Cleerly Unveils PowerScribe Integration and Lesion-Level Reporting at RSNA 2025

New additions streamline data transfer with lesion details, helping make information more accessible for care teams DENVER–(BUSINESS WIRE)–#AI—Cleerly, a leader in AI-based cardiovascular imaging, will showcase new product updates at RSNA 2025, November 30 – December 4, 2025, at McCormick Place in Chicago, IL. At Booth #8039, Cleerly will demonstrate PowerScribe integration and newly added … [Read more…]

IMFINZI® approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers

Based on MATTERHORN Phase III trial results which showed a 29% reduction in the risk of progression, recurrence or death and a 22% reduction in the risk of death for the IMFINZI regimen vs. chemotherapy alone WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) has been approved … [Read more…]

Keepit Successfully Completes TISAX Audit, Demonstrating Commitment to Trusted Information Security

COPENHAGEN, Denmark–(BUSINESS WIRE)–Keepit, the leader in SaaS data protection, today announced that it has successfully completed the Trusted Information Security Assessment Exchange (TISAX) audit — achieving excellent results with no major findings. TISAX (Trusted Information Security Assessment Exchange) is a European standard for information security assessments developed by the German Association of the Automotive Industry … [Read more…]

Otsuka Receives FDA Accelerated Approval for VOYXACT® (sibeprenlimab-szsi) for the Reduction of Proteinuria in Adults with Primary Immunoglobulin A Nephropathy (IgAN) at Risk for Disease Progression

VOYXACT achieved a significant placebo-adjusted treatment effect of 51% (P<0.0001) reduction in proteinuria at 9 months of treatment (-50% VOYXACT vs 2% placebo) in the VISIONARY Phase 3 interim analysis. In the study, the most common adverse reactions (reported in ≥10% of patients treated with VOYXACT and at a higher incidence than placebo) reported in … [Read more…]

Piroxicam (CAS 36322-90-4) Industry Research Report 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 – Applications, Pricing, Manufacturers, End-Users, and Downstream Trends – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Piroxicam (CAS 36322-90-4) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029” report has been added to ResearchAndMarkets.com’s offering. This report on Piroxicam provides comprehensive insights, including general information, synonyms, chemical composition, safety, hazards, handling, storage, and toxicological and ecological details, along with transport information. This in-depth study serves … [Read more…]

BostonGene to Showcase Transformative Impact of AI-Driven Profiling with Six Abstracts at the 67th American Society of Hematology Annual Meeting & Exposition

AI-Powered Multimodal Profiling Accelerates Mechanism Discovery, Patient Stratification and Biomarker-Driven Therapeutic Development in Hematologic Malignancies WALTHAM, Mass.–(BUSINESS WIRE)–BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced the selection of two abstracts for oral presentation, three abstracts for poster presentation and one abstract for online publication at the 67th American Society of … [Read more…]

Satellos to Participate in December Investor Conferences

TORONTO–(BUSINESS WIRE)–Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will participate in the following investor conferences: Piper Sandler 37th Annual Healthcare Conference (New York, NY) Date: Wednesday, Dec. 3, 2025 Time: 12:50 p.m. ET Format: Presentation … [Read more…]

Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes

WALTHAM, Mass.–(BUSINESS WIRE)–Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of €2.1 billion aggregate principal amount (the “Offering”) of the following euro-denominated notes, which will be issued by Thermo Fisher Scientific (Finance I) B.V., its indirect, wholly-owned finance subsidiary: €1,000,000,000 aggregate principal amount of its floating rate … [Read more…]

AHS Announces 2025 Scottsdale Headache Symposium® Featuring New Clinical Insights and Emerging Science in Headache Medicine

MOUNT ROYAL, N.J.–(BUSINESS WIRE)–#AHSAZ–The American Headache Society® (AHS), a professional society of healthcare providers dedicated to the study and treatment of headache and face pain, will host the 2025 Scottsdale Headache Symposium December 4-7 in Scottsdale, Arizona. This year’s meeting brings together physicians, scientists, and advanced practitioners for an immersive educational experience designed to elevate … [Read more…]